The marketing authorisation for Riprazo has been withdrawn at the request of the marketing-authorisation holder.
Riprazo : EPAR - Summary for the public (PDF/187.23 KB)
First published: 07/05/2009
Last updated: 20/09/2012
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Novartis Europharm Ltd.
|Date of issue of marketing authorisation valid throughout the European Union||
Novartis Europharm Limited
West Sussex, RH12 5AB
17/08/2012 Riprazo - EMEA/H/C/000853 - IG/0209/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Agents acting on the renin-angiotensin system
Treatment of essential hypertension.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 201217/02/2012
European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines17/02/2012
European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study22/12/2011
European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines19/02/2009